Tommie Richardson, MD
Addiction Medicine · Smyrna, GANPI 1013006584
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $9,096 of the $13,671 with a category attached, or 66.5%. 30 manufacturers reported payments, led by MDD US Operations, LLC at 38.5% of the total. Reporting peaked in 2019 at $6,435 and has fallen 95.9% since, to $264 in 2025. Among addiction medicine clinicians in GA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 371 payments — averaging $36.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- MDD US Operations, LLC$5K
- AbbVie$2K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1K
- Otsuka America Pharmaceutical, Inc.$1K
- Alkermes, Inc.$888
- Lundbeck LLC$545
- plus $3K from 24 others
Across 1 payment — averaging $150.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Indivior Inc.$150
What the payments were for
- Consulting fees$3,57526%
- Travel & lodging$9957%
- Food & beverage$9,09667%
- Education$50%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| MDD US Operations, LLC | 18 | $5,259 |
| AbbVie(2 entities) | 71 | $1,656 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 33 | $1,116 |
| Otsuka America Pharmaceutical, Inc. | 40 | $1,061 |
| Alkermes, Inc. | 30 | $888 |
| Lundbeck LLC | 30 | $545 |
| Johnson & Johnson | 16 | $509 |
| Teva Pharmaceuticals USA, Inc. | 31 | $430 |
| Sunovion Pharmaceuticals Inc. | 18 | $356 |
| Vanda Pharmaceuticals Inc. | 12 | $317 |
| Takeda Pharmaceuticals U.S.A., Inc. | 13 | $258 |
| Axsome Therapeutics, Inc. | 6 | $215 |
| Braeburn Inc. | 2 | $163 |
| Corium, LLC | 9 | $153 |
| Orexo US, Inc. | 8 | $129 |
| Indivior Inc. | 5 | $106 |
| Supernus Pharmaceuticals, Inc. | 4 | $84 |
| Neos Therapeutics, LP | 4 | $57 |
| Merck | 3 | $55 |
| Almatica Pharma LLC | 3 | $48 |
| Jazz Pharmaceuticals Inc. | 2 | $46 |
| Ironshore Pharmaceuticals Inc. | 2 | $43 |
| Kaleo, Inc. | 3 | $38 |
| Idorsia Pharmaceuticals US Inc | 2 | $33 |
| Bausch Health US, LLC | 1 | $24 |
| Neurocrine Biosciences, Inc. | 1 | $21 |
| Tris Pharma Inc | 1 | $19 |
| Aytu Biopharma, Inc. | 1 | $16 |
| Arbor Pharmaceuticals, Inc. | 1 | $15 |
| Eisai Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Lucemyra/Lofexidine$4,999
- LYBALVI$996
- ARISTADA$442
- CAPLYTA$414
- VRAYLAR$364
- REXULTI$338
- BRIXADI$145
- Auvelity$125
- INVEGA SUSTENNA$120
- SPRAVATO$116
- ARISTADA INITIO$110
How this compares
$13,671 in reported general payments places this provider in the 95th percentile of 35 addiction medicine providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega SustennaPaliperidone Palmitate | 48 | $139,543 |
| AustedoDeutetrabenazine | 24 | $137,366 |
| VraylarCariprazine Hcl | 60 | $100,937 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 186 | $33,479 |
| Lurasidone Hcl | 18 | $6,983 |
| ZubsolvBuprenorphine Hcl/Naloxone Hcl | 12 | $4,538 |
| Aripiprazole | 59 | $2,105 |
| Gabapentin | 157 | $1,514 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 18 | $1,501 |
| Trazodone Hcl | 121 | $1,096 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 45 | $1,085 |
| Atomoxetine Hcl | 24 | $1,026 |
| Bupropion XlBupropion Hcl | 54 | $1,026 |
| Buprenorphine Hcl | 38 | $1,017 |
| Divalproex Sodium | 66 | $989 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Sustenna | $509 | $139,54348 claims |
| Teva Pharmaceuticals USA, Inc.Austedo | $430 | $137,36624 claims |
| AbbVieVraylar | $1,656 | $100,93760 claims |
| Orexo US, Inc.Zubsolv | $129 | $4,53812 claims |
| Almatica Pharma LLCSertraline Hcl | $48 | $66398 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 35 addiction medicine providers in Georgia.
Other addiction medicine in Smyrna
- Kimberlynn RichardsSmyrna$14K
- Daniel GolightlySmyrna$2K
- Derek KlemmDemorest$5K
- Scott MilesSt.mary's$887
- Roy AryAtlanta$749
- Ajibola BabatundeAcworth$549
- Patrice MarshallDecatur$453
- Stacy SeikelDahlonega$414
- Claire TuckerStatesboro$352
- Sabrina HannaDahlonega$271
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.